JP4671956B2 - ガリウム−68を得る方法及びガリウム−68放射標識錯体を製造する方法、並びにガリウム−68調整キット及びその使用 - Google Patents
ガリウム−68を得る方法及びガリウム−68放射標識錯体を製造する方法、並びにガリウム−68調整キット及びその使用 Download PDFInfo
- Publication number
- JP4671956B2 JP4671956B2 JP2006506105A JP2006506105A JP4671956B2 JP 4671956 B2 JP4671956 B2 JP 4671956B2 JP 2006506105 A JP2006506105 A JP 2006506105A JP 2006506105 A JP2006506105 A JP 2006506105A JP 4671956 B2 JP4671956 B2 JP 4671956B2
- Authority
- JP
- Japan
- Prior art keywords
- generator
- anion exchanger
- chelating agent
- gallium
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 title 3
- 239000002738 chelating agent Substances 0.000 claims description 58
- 150000001450 anions Chemical class 0.000 claims description 25
- 230000008685 targeting Effects 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 21
- 230000001588 bifunctional effect Effects 0.000 claims description 18
- 239000000700 radioactive tracer Substances 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 150000002500 ions Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 claims description 4
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 108010028921 Lipopeptides Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 239000012609 strong anion exchange resin Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- 238000012636 positron electron tomography Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- -1 68 Ga Chemical class 0.000 description 7
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- RZHKDBRREKOZEW-AAXZNHDCSA-N 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl] Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 RZHKDBRREKOZEW-AAXZNHDCSA-N 0.000 description 4
- 108700038672 Edotreotide Proteins 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000000163 radioactive labelling Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 4
- KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 150000004696 coordination complex Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- VXAUWWUXCIMFIM-UHFFFAOYSA-M aluminum;oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Al+3] VXAUWWUXCIMFIM-UHFFFAOYSA-M 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- SQKUFYLUXROIFM-UHFFFAOYSA-N 2-[2-[carboxymethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino]acetic acid Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC=2C(=C(C)N=CC=2COP(O)(O)=O)O)CC(O)=O)=C1O SQKUFYLUXROIFM-UHFFFAOYSA-N 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100465550 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRE2 gene Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000011847 diagnostic investigation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002019 disulfides Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D59/00—Separation of different isotopes of the same chemical element
- B01D59/28—Separation by chemical exchange
- B01D59/30—Separation by chemical exchange by ion exchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B3/00—Extraction of metal compounds from ores or concentrates by wet processes
- C22B3/20—Treatment or purification of solutions, e.g. obtained by leaching
- C22B3/42—Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B58/00—Obtaining gallium or indium
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B59/00—Obtaining rare earth metals
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
- G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for
- G21H5/02—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for as tracers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P10/00—Technologies related to metal processing
- Y02P10/20—Recycling
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Environmental & Geological Engineering (AREA)
- Geology (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- Geochemistry & Mineralogy (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Led Devices (AREA)
- Catalysts (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Description
J.Schuhmacher et al.J.appl.Radiat.Isotopes 32,1981,31−36
a)68Ge/68Gaジェネレーターからの溶出液を、対イオンとしてHCO3 −を含む陰イオン交換体と接触させ、前記陰イオン交換体から68Ga3+を溶出することによって68Gaを得ること、及び
b)その68Gaをキレート剤と反応させることにより68Ga放射標識錯体を製造する方法である。
c)68Ge/68Gaジェネレーターからの溶出液を、対イオンとしてHCO3 −を含む陰イオン交換体と接触させ、前記陰イオン交換体から68Gaを溶出することによって68Gaを得ること、及び
d)反応を、マイクロ波活性化を使用して行い、その68Gaをキレート剤と反応させることにより、68Ga放射標識錯体を製造する方法である。
二酸化チタンカラムによる68Ge/68Gaジェネレーターから、0.1MのHCl(5〜6mL)を使用して68Gaを溶出した。その溶出液を、HClによって酸性化し、対イオンとしてのHCO3 −及び第四級アミン官能基を含むポリスチレン−ジビニルベンゼン系強塩基性の陰イオン交換樹脂(SPEカートリッジChromafix 30−PS−HCO3、Macharey−Nagel、ドイツ)を含有するカートリッジにかけた。99%を超える68Ga放射能がその樹脂に保持され、次いで200μlのH2Oで溶出した。
実施例1で得た溶出液を、対イオンとしてのCl−及び第四級アミン官能基を含む強塩基性の陰イオン交換樹脂(SAX SPEC、50mg、1mL、Isolute、英国、及びSAX SPEC、15mg、3mL、NTK kemi、米国)を含有するカートリッジにかけた。両方のイオン交換体とも、68Ga放射能の保持をなんら示さなかった。
比較例1aにおいて使用したカートリッジのCl−対イオンをOH−対イオンと交換して、例1aの記載と同様にこの比較例を行った。68Ga放射能の保持は、10〜20%であった。
DOTA−D−Phe 1 −Tyr 3 −オクトレオチド(DOTA−TOC)の 68 Ga放射標識の比較研究
本発明の方法により得た68Ga及びさらなる陰イオン交換処理をしないで68Ge/68Gaジェネレーターから得た68Gaを、DOTA−D−Phe1−Tyr3−オクトレオチド(DOTA−TOC)の68Ga放射標識に使用した。
酢酸ナトリウムを68Ge/68Gaジェネレーターからの溶出液に(36mgを1mLに)加え、約5.5のpHに調整し、その混合物をよくかき混ぜた。DOTA−TOC(20nmol)を加え、その混合物を96℃で25分間加熱した。その反応混合物を室温まで冷却し、C−18 SPEカラム(HyperSEP S C18)にかけ、それを次に2mLの水で洗浄し、生成物をエタノール:水=50:50(1mL)により溶出した。
実施例で得た200μlの68Gaに酢酸ナトリウムを加えて約5.5のpHに調整した。錯体形成反応を、10nmolのDOTATOCを使用して実施例2a)に記載したようにして行った。
本発明の方法で得た68Gaを使用すると、放射標識錯体の合成に必要なDOTATOCの量が減し、従って、3倍を超える比放射能を増加させることが可能であった。
Claims (19)
- 68Ge/68Gaジェネレーターからの溶出液を、対イオンとしてHCO3 -を含む陰イオン交換体と接触させ、陰イオン交換体から68Gaを溶出することによって68Gaを得る方法。
- 68Ge/68Gaジェネレーターが二酸化チタンを含んでなるカラムを備える、請求項1記載の方法。
- 68Ge/68Gaジェネレーターからの68Gaの溶出に0.05〜5MのHClを使用する、請求項1記載の方法。
- 68Ge/68Gaジェネレーターからの68Gaの溶出に0.05〜0.1MのHClを使用する、請求項2記載の方法。
- 前記陰イオン交換体から68Gaの溶出に水を使用する、請求項1乃至請求項4のいずれか1項記載の方法。
- 前記陰イオン交換体が第四級アミン官能基を含む強陰イオン交換体である、請求項1乃至請求項5のいずれか1項記載の方法。
- 前記陰イオン交換体がポリスチレン−ジビニルベンゼン系強陰イオン交換樹脂である、請求項1乃至請求項6のいずれか1項記載の方法。
- 請求項1乃至請求項7のいずれか1項記載の方法で得た68Gaをキレート剤と反応させることによって68Ga放射標識錯体を製造する方法。
- 前記キレート剤が大環状キレート剤である、請求項8記載の方法。
- 前記キレート剤がO及びNから選択される硬いドナー原子を含む、請求項8又は請求項9記載の方法。
- 前記キレート剤が二官能性キレート剤である、請求項8乃至請求項10のいずれか1項記載の方法。
- 前記キレート剤が、タンパク質、糖タンパク質、リポタンパク質、ポリペプチド、糖ポリペプチド、リポポリペプチド、ペプチド、糖ペプチド、リポペプチド、炭水化物、核酸、オリゴヌクレオチド又はこれらの化合物の一部、断片、誘導体若しくは複合体、及び小さな有機分子からなる群から選択されるターゲティングベクターを含む二官能性キレート剤である、請求項11記載の方法。
- 前記反応をマイクロ波活性化を用いて実施する、請求項8乃至請求項12のいずれか1項記載の方法。
- 68Ga放射標識PETトレーサーを製造するための、請求項8乃至請求項13のいずれか1項記載の方法。
- 68Ge/68Gaジェネレーターからの68Gaの調製用キットであって、ジェネレーターカラムと、対イオンとしてHCO3 -を含んでなる陰イオン交換体を含む第2のカラムとを備えるキット。
- 前記カラム同士を直列に連結する手段をさらに備える、請求項15記載のキット。
- ジェネレーターカラムから68Gaを溶出するためのHCl水溶液及び/又は陰イオン交換体から68Gaを溶出するための水をさらに備えている、請求項15又は請求項16記載のキット。
- キレート剤をさらに備える、請求項15乃至請求項17のいずれか1項記載のキット。
- 68Ga放射標識PETトレーサーを製造するための請求項18記載のキットの使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0308407.6A GB0308407D0 (en) | 2003-04-11 | 2003-04-11 | Method of obtaining 68 GA |
PCT/GB2004/001548 WO2004089517A1 (en) | 2003-04-11 | 2004-04-08 | Method of obtaining galliun-68 and use thereof and device for carrying out saif method |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006526764A JP2006526764A (ja) | 2006-11-24 |
JP4671956B2 true JP4671956B2 (ja) | 2011-04-20 |
Family
ID=9956633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006506105A Expired - Lifetime JP4671956B2 (ja) | 2003-04-11 | 2004-04-08 | ガリウム−68を得る方法及びガリウム−68放射標識錯体を製造する方法、並びにガリウム−68調整キット及びその使用 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070031329A1 (ja) |
EP (1) | EP1610886B1 (ja) |
JP (1) | JP4671956B2 (ja) |
KR (1) | KR20050119205A (ja) |
CN (1) | CN100381196C (ja) |
AT (1) | ATE448863T1 (ja) |
AU (1) | AU2004228745B2 (ja) |
BR (1) | BRPI0409114A (ja) |
CA (1) | CA2520176C (ja) |
DE (1) | DE602004024181D1 (ja) |
DK (1) | DK1610886T3 (ja) |
ES (1) | ES2336447T3 (ja) |
GB (1) | GB0308407D0 (ja) |
IL (2) | IL170863A (ja) |
MX (1) | MXPA05010855A (ja) |
NO (1) | NO20054614L (ja) |
RU (1) | RU2343965C2 (ja) |
WO (1) | WO2004089517A1 (ja) |
ZA (1) | ZA200508726B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004057225B4 (de) * | 2004-11-26 | 2006-10-12 | Johannes-Gutenberg-Universität Mainz | Verfahren und Vorrichtung zur Isolierung eines chemisch und radiochemisch gereinigten 68Ga-Radionuklids und zum Markieren eines Markierungsvorläufers mit dem 68Ga-Radionuklid |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
US7586102B2 (en) | 2006-08-14 | 2009-09-08 | Board Of Regents The University Of Texas System | Automated system for formulating radiopharmaceuticals |
JP5005024B2 (ja) * | 2007-03-02 | 2012-08-22 | 国立大学法人 長崎大学 | Ge吸着剤 |
EP2214720B1 (en) | 2007-12-03 | 2018-11-28 | GE Healthcare Limited | Purification of 68ge/68ga generator eluate from fe(iii) intended to improve specific radioactivity of 68ga-based radiopharmaceuticals |
KR101051084B1 (ko) | 2009-09-14 | 2011-07-21 | 서울대학교산학협력단 | [18f]폴리프라이드의 개선된 제조방법 |
GB0922492D0 (en) * | 2009-12-23 | 2010-02-03 | Hammersmith Imanet Ltd | Method for obtaining 68GA |
US9715020B2 (en) * | 2010-04-09 | 2017-07-25 | Bayer Healthcare Llc | Radiopharmaceutical concentration measurement system and method |
GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
TWI397421B (zh) * | 2010-07-14 | 2013-06-01 | Inst Nuclear Energy Res Atomic Energy Council | 鎵-68放射性同位素產生裝置及其方法 |
CN101890297B (zh) * | 2010-07-16 | 2012-06-27 | 中国人民解放军第四军医大学 | 一种放射性核素镓-68的浓缩纯化方法 |
RU2464043C1 (ru) * | 2011-09-26 | 2012-10-20 | Федеральное государственное бюджетное учреждение "Федеральный медицинский биофизический центр имени А.И. Бурназяна" | СПОСОБ ПОЛУЧЕНИЯ РАСТВОРОВ 68Ga ВЫСОКОЙ ЧИСТОТЫ |
WO2013082699A1 (en) | 2011-12-08 | 2013-06-13 | Nordion (Canada) Inc. | Method of pre-treating an adsorbent for a chromatographic separation |
RU2522892C1 (ru) * | 2013-01-09 | 2014-07-20 | Российская Федерация, от имени которой выступает Государственная корпорация по атомной энергии "Росатом" | Способ получения активной фармацевтической субстанции для синтеза препаратов галлия-68 |
US9266084B2 (en) * | 2013-06-13 | 2016-02-23 | Institute Of Nuclear Energy Research | Automatic synthesizer apparatus for producing radiopharmaceutical tumor imaging agent Gallium-68-DOTATATE and method thereof |
KR102490458B1 (ko) | 2015-01-30 | 2023-01-19 | 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. | 68Ge/68Ga 발생기로부터 유래하는 용출물로부터 Ga-68을 정제하는 방법 및 이러한 방법에 사용하기 위한 크로마토그래피 컬럼 |
CN106328237B (zh) * | 2015-06-29 | 2019-04-23 | 中国辐射防护研究院 | 一种放射性废离子交换树脂微波碳化、灰化工艺及专用装置 |
WO2017144959A1 (pt) * | 2016-02-23 | 2017-08-31 | Serviço Nacional De Aprendizagem Industrial - Senai. | Equipamento para marcação de moléculas com gálio-68 |
WO2018039662A1 (en) * | 2016-08-26 | 2018-03-01 | Mayo Foundation For Medical Education And Research | Rapid isolation of cyclotron-produced gallium-68 |
WO2020028825A1 (en) * | 2018-08-03 | 2020-02-06 | Board Of Regents, The University Of Texas System | Method for extraction and purification of 68ga |
US20220351873A1 (en) * | 2019-10-12 | 2022-11-03 | Artms Products, Inc. | Systems and methods of isolation of gallium-68 |
RU2714497C1 (ru) * | 2019-12-02 | 2020-02-18 | Общество с ограниченной ответственностью "НТЦ Амплитуда" | Применение ионообменных картриджей типа Chromafix HR-XC в Н+-форме и Chromafix 30-PS в НСО3-форме в устройстве для очистки и концентрирования элюата генератора 68Ge/68Ga |
CN113144225A (zh) * | 2021-03-30 | 2021-07-23 | 广东回旋医药科技股份有限公司 | 一种高放射性核纯度的68Ga-GaCl3溶液的制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4928320A (ja) * | 1972-07-04 | 1974-03-13 | ||
JPH11130431A (ja) * | 1997-10-30 | 1999-05-18 | Hamamatsu Photonics Kk | 無水塩化ガリウム68およびポルフィリン誘導体のガリウム68錯体 |
US6071490A (en) * | 1998-05-07 | 2000-06-06 | Immunomedics, Inc. | Position emission tomography using gallium-68 chelates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4288424A (en) * | 1979-01-15 | 1981-09-08 | Massachusetts Institute Of Technology | Generator for ionic gallium-68 based on column chromatography |
DE2932948C2 (de) * | 1979-08-14 | 1982-11-18 | Stiftung Deutsches Krebsforschungszentrum, 6900 Heidelberg | Verfahren zur Herstellung eines Ionenaustauschers und dessen Verwendung |
US4330507A (en) * | 1980-06-11 | 1982-05-18 | New England Nuclear Corporation | Method and system for generating and collecting gallium-68 using alkaline eluant |
DE4231622C2 (de) * | 1992-09-22 | 1996-09-05 | Bakelite Ag | Verfahren zur Herstellung von Metallneutralkomplexen mit hoher Koordinationszahl und deren Verwendung |
US7011816B2 (en) * | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
-
2003
- 2003-04-11 GB GBGB0308407.6A patent/GB0308407D0/en not_active Ceased
-
2004
- 2004-04-08 US US10/552,206 patent/US20070031329A1/en not_active Abandoned
- 2004-04-08 EP EP04726535A patent/EP1610886B1/en not_active Expired - Lifetime
- 2004-04-08 WO PCT/GB2004/001548 patent/WO2004089517A1/en active Application Filing
- 2004-04-08 ES ES04726535T patent/ES2336447T3/es not_active Expired - Lifetime
- 2004-04-08 MX MXPA05010855A patent/MXPA05010855A/es active IP Right Grant
- 2004-04-08 RU RU2005130865/15A patent/RU2343965C2/ru not_active IP Right Cessation
- 2004-04-08 AT AT04726535T patent/ATE448863T1/de not_active IP Right Cessation
- 2004-04-08 BR BRPI0409114-0A patent/BRPI0409114A/pt not_active IP Right Cessation
- 2004-04-08 CA CA2520176A patent/CA2520176C/en not_active Expired - Fee Related
- 2004-04-08 CN CNB2004800095966A patent/CN100381196C/zh not_active Expired - Lifetime
- 2004-04-08 DK DK04726535.0T patent/DK1610886T3/da active
- 2004-04-08 KR KR1020057019261A patent/KR20050119205A/ko not_active Application Discontinuation
- 2004-04-08 JP JP2006506105A patent/JP4671956B2/ja not_active Expired - Lifetime
- 2004-04-08 DE DE602004024181T patent/DE602004024181D1/de not_active Expired - Lifetime
- 2004-04-08 AU AU2004228745A patent/AU2004228745B2/en not_active Ceased
-
2005
- 2005-09-14 IL IL170863A patent/IL170863A/en not_active IP Right Cessation
- 2005-10-07 NO NO20054614A patent/NO20054614L/no not_active Application Discontinuation
- 2005-10-27 ZA ZA200508726A patent/ZA200508726B/en unknown
-
2009
- 2009-05-21 IL IL198894A patent/IL198894A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4928320A (ja) * | 1972-07-04 | 1974-03-13 | ||
JPH11130431A (ja) * | 1997-10-30 | 1999-05-18 | Hamamatsu Photonics Kk | 無水塩化ガリウム68およびポルフィリン誘導体のガリウム68錯体 |
US6071490A (en) * | 1998-05-07 | 2000-06-06 | Immunomedics, Inc. | Position emission tomography using gallium-68 chelates |
Also Published As
Publication number | Publication date |
---|---|
CN1780679A (zh) | 2006-05-31 |
IL198894A0 (en) | 2010-02-17 |
MXPA05010855A (es) | 2005-12-14 |
AU2004228745B2 (en) | 2009-06-11 |
EP1610886B1 (en) | 2009-11-18 |
DK1610886T3 (da) | 2010-03-29 |
RU2343965C2 (ru) | 2009-01-20 |
RU2005130865A (ru) | 2006-06-10 |
AU2004228745A1 (en) | 2004-10-21 |
EP1610886A1 (en) | 2006-01-04 |
JP2006526764A (ja) | 2006-11-24 |
CA2520176C (en) | 2012-06-05 |
ZA200508726B (en) | 2007-07-25 |
NO20054614L (no) | 2005-10-07 |
CA2520176A1 (en) | 2004-10-21 |
DE602004024181D1 (de) | 2009-12-31 |
IL170863A (en) | 2012-01-31 |
CN100381196C (zh) | 2008-04-16 |
ES2336447T3 (es) | 2010-04-13 |
KR20050119205A (ko) | 2005-12-20 |
US20070031329A1 (en) | 2007-02-08 |
ATE448863T1 (de) | 2009-12-15 |
BRPI0409114A (pt) | 2006-04-04 |
WO2004089517A1 (en) | 2004-10-21 |
GB0308407D0 (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4671956B2 (ja) | ガリウム−68を得る方法及びガリウム−68放射標識錯体を製造する方法、並びにガリウム−68調整キット及びその使用 | |
ZA200508727B (en) | Microwave method for preparing radiolabelled gallium complexes | |
US8663597B2 (en) | Method for obtaining 68Ga | |
JP2002500639A (ja) | 腫瘍造影剤としてのヌクレオチドポリリン酸に結合された放射性核種 | |
US20100256331A1 (en) | 68Ga-Labelling of a Free and Macromolecule Conjugated Macrocyclic Chelator at Ambient Temperature | |
JP3812680B2 (ja) | 放射性医薬用途のペプチド類およびタンパク質類の安定化 | |
KR102269315B1 (ko) | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 | |
Varvarigou et al. | Development of radioactively labelled cancer seeking biomolecules for targeted radiotherapy | |
Fisher | Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma | |
Varvarigou et al. | Development of radioactively labelled cancer seeking biomolecules for targeted radiotherapy. Greece | |
AU1429392A (en) | In situ synthesis of radiopharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100427 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100727 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100727 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100727 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100827 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101013 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101221 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4671956 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |